Clinical Trial Update: Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing pazopanib to temsirolimus in poor-risk clear-cell renal cell carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-20